KALV - カ―ビラン・セラピュ―ティクス (KalVista Pharmaceuticals Inc.) カ―ビラン・セラピュ―ティクス

 KALVのチャート


 KALVの企業情報

symbol KALV
会社名 KalVista Pharmaceuticals Inc (カ―ビラン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 KalVista Pharmaceuticals Inc. formerly Carbylan Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery development and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate KVD818 is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.   カ―ビラン・セラピュ―ティクスは、米国のバイオ医薬品会社。満たされていない医療ニ―ズに対応する併用療法の開発と商業化に焦点を当て事業を展開する。変形性膝関節症に関連する痛みを治療するための医薬品として、関節内注射用製品候補であるハイドロス-TAを提供する。本社所在地はカリフォルニア州。   
本社所在地 55 Cambrigge Parkway Suite 901E Cambridge MA 02142 USA
代表者氏名 Richard Aldrich リチャード・アルドリッチ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 857-999-0075
設立年月日 38047
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 33人
url www.kalvista.com
nasdaq_url https://www.nasdaq.com/symbol/kalv
adr_tso
EBITDA EBITDA(百万ドル) -20.06300
終値(lastsale) 17.465
時価総額(marketcap) 300043233.455
時価総額 時価総額(百万ドル) 339.64240
売上高 売上高(百万ドル) 12.01600
企業価値(EV) 企業価値(EV)(百万ドル) 291.78640
当期純利益 当期純利益(百万ドル) -15.90700
決算概要 決算概要 BRIEF: For the three months ended 31 July 2018 Kalvista Pharmaceuticals Inc revenues increased from $96K to $3.7M. Net loss increased 2% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $3.5M to $8.4M (expense) General and administrative increase of 14% to $2.4M (expense).

 KALVのテクニカル分析


 KALVのニュース

   KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors  2021/03/19 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and bus
   KalVista Pharmaceuticals Reports Third Fiscal Quarter Results  2021/03/11 11:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2021. “We are making excellent progress in our commitment to providing those with hereditary angioedema a complete set of oral options to man
   KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference  2021/02/18 12:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 9:20 a.m. ET. A live webcast of the presentations will be available on the Company’s website at www.kalvist
   KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares  2021/02/16 21:01:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 806,250 additional shares of KalVista’s common stock. After giving effect to the full exercise of the
   KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development  2021/02/11 07:18:00 Benzinga
KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising …
   KalVista Pharmaceuticals Reports Third Fiscal Quarter Results  2021/03/11 11:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2021. “We are making excellent progress in our commitment to providing those with hereditary angioedema a complete set of oral options to man
   KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference  2021/02/18 12:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 9:20 a.m. ET. A live webcast of the presentations will be available on the Company’s website at www.kalvist
   KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares  2021/02/16 21:01:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 806,250 additional shares of KalVista’s common stock. After giving effect to the full exercise of the
   KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development  2021/02/11 07:18:00 Benzinga
KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising …
   KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock  2021/02/11 02:52:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $193.5 million. In addition, KalVista has granted the underwriter
   KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference  2021/02/18 12:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 9:20 a.m. ET. A live webcast of the presentations will be available on the Company’s website at www.kalvist
   KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares  2021/02/16 21:01:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,250 shares of its common stock at a price to the public of $36.00 per share before underwriting discounts and commissions, which included the exercise in full by the underwriters of their option to purchase 806,250 additional shares of KalVista’s common stock. After giving effect to the full exercise of the
   KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development  2021/02/11 07:18:00 Benzinga
KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising …
   KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock  2021/02/11 02:52:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $193.5 million. In addition, KalVista has granted the underwriter
   The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs  2021/02/10 12:34:42 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) AngioDynamics, Inc. (NASDAQ: ANGO ) argenx SE – ADR (NASDAQ: ARGX ) Arcus Biosciences Inc (NYSE: RCUS ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) Assertio Holdings Inc (NASDAQ: ASRT ) Bausch Health Companies Inc (NYSE: BHC ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Celcuity Inc (NASDAQ: CELC ) Cellular Biomedicine Group Inc (NASDAQ: CBMG ) ChemoCentryx Inc (NASDAQ: CCXI ) Chimerix Inc (NASDAQ: CMRX ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Corcept Therapeutics Incorporated (NASDAQ: CORT ) DarioHealth Corp (NASDAQ: DRIO ) Edap Tms SA (NASDAQ: EDAP ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evogene Ltd (NASDAQ: EVGN ) Eyenovia Inc (NASDAQ: EYEN ) Glaukos Corp (NYSE: GKOS ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Haemonetics Corporation (NYSE: HAE ) Fulgent Genetics Inc (NASDAQ: FLGT ) Halozyme Therapeutics, Inc.

 関連キーワード  (医薬品 米国株 カ―ビラン・セラピュ―ティクス KALV KalVista Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)